"antisclerostin" meaning in All languages combined

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "anti",
        "3": "sclerostin"
      },
      "expansion": "anti- + sclerostin",
      "name": "prefix"
    }
  ],
  "etymology_text": "From anti- + sclerostin.",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "antisclerostin (not comparable)",
      "name": "en-adj"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "adj",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "English terms prefixed with anti-",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with 1 entry",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with entries",
          "parents": [],
          "source": "w"
        }
      ],
      "examples": [
        {
          "ref": "2015 June 12, Ioanna Papathanasiou et al., “DNA methylation regulates sclerostin (SOST) expression in osteoarthritic chondrocytes by bone morphogenetic protein 2 (BMP-2) induced changes in Smads binding affinity to the CpG region of SOST promoter”, in Arthritis Research & Therapy, volume 17, →DOI:",
          "text": "However, in OA the findings in preclinical studies using antisclerostin therapy have been disappointing, as genetic absence of sclerostin or antisclerostin therapy with monoclonal antibody had no impact on articular cartilage remodeling in animals with age-dependent OA or post-traumatic OA, respectively [ 32 ].",
          "type": "quote"
        }
      ],
      "glosses": [
        "That counters the effect of sclerostin"
      ],
      "id": "en-antisclerostin-en-adj-TivCoRHb",
      "links": [
        [
          "sclerostin",
          "sclerostin"
        ]
      ],
      "tags": [
        "not-comparable"
      ]
    }
  ],
  "word": "antisclerostin"
}

{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "anti",
        "3": "sclerostin"
      },
      "expansion": "anti- + sclerostin",
      "name": "prefix"
    }
  ],
  "etymology_text": "From anti- + sclerostin.",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "antisclerostin (not comparable)",
      "name": "en-adj"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "adj",
  "senses": [
    {
      "categories": [
        "English adjectives",
        "English entries with incorrect language header",
        "English lemmas",
        "English terms prefixed with anti-",
        "English terms with quotations",
        "English uncomparable adjectives",
        "Pages with 1 entry",
        "Pages with entries"
      ],
      "examples": [
        {
          "ref": "2015 June 12, Ioanna Papathanasiou et al., “DNA methylation regulates sclerostin (SOST) expression in osteoarthritic chondrocytes by bone morphogenetic protein 2 (BMP-2) induced changes in Smads binding affinity to the CpG region of SOST promoter”, in Arthritis Research & Therapy, volume 17, →DOI:",
          "text": "However, in OA the findings in preclinical studies using antisclerostin therapy have been disappointing, as genetic absence of sclerostin or antisclerostin therapy with monoclonal antibody had no impact on articular cartilage remodeling in animals with age-dependent OA or post-traumatic OA, respectively [ 32 ].",
          "type": "quote"
        }
      ],
      "glosses": [
        "That counters the effect of sclerostin"
      ],
      "links": [
        [
          "sclerostin",
          "sclerostin"
        ]
      ],
      "tags": [
        "not-comparable"
      ]
    }
  ],
  "word": "antisclerostin"
}